Saidal Group's $1 billion roadmap for the pharmaceutical industry
Saidal Group, Algeria's national leader in pharmaceuticals, is implementing a rigorous roadmap to achieve national self-sufficiency and reach a turnover of $1 billion. This initiative comes as Algeria faces an annual import bill exceeding 75 billion dinars for antibiotics. The new factory in Harbil, M茅d茅a province, is central to this strategy, focusing on manufacturing raw materials for antibiotics. Younes Bouarara, Director General of Saidal Group, conducted a follow-up visit on August 24, 2026, to accelerate the construction of this strategic complex. Guided by the Minister of Pharmaceutical Industry, Dr. Ouacim Kouidri, the project aims to reduce Algeria's dependence on foreign imports for public health needs. The country currently spends approximately 75.4 billion dinars annually on antimicrobial treatments from international markets. By integrating local production of active ingredients, the Harbil complex seeks to curb this outflow of foreign currency, ensure autonomous healthcare provision, and strengthen the industrial sector. Beyond its health implications, this infrastructure is expected to drive significant economic transformation for Saidal, aiming for sustained growth and a symbolic turnover of $1 billion. The strategy involves consolidating supplies for Algerian pharmacies and hospitals, then expanding production to regional and international markets. Strict oversight of the construction progress is maintained to prevent delays, with the factory's timely launch
